Company profile
Elicio Therapeutics, Inc.
NASDAQ: ELTX · Healthcare · Biotechnology
#779 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
24DFH 21DQ 23GM —SS 43
v0.1 · 55/100 weight · provisional
↑ market scale, workforce scale · ↓ return on equity, disclosure history
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$39.6M
Employees
33
as of 2026-08-19
Market cap
$59.3M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.3M$2.3M2022
Net income-$39.6M-$39.6M2025
Operating income-$37.7M-$37.7M2025
Total assets$25.9M$25.9M2025
Liabilities$24.2M$24.2M2025
Equity$1.6M$1.6M2025
Revenue trend
FY2021 – FY2022 · USD
FY21
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Elicio Therapeutics, Inc.’s revenue?
Elicio Therapeutics, Inc. booked $2.3M in FY2022 revenue, contracting 92% year over year — slower than 90% of Healthcare companies we track, at a -1719.7% net margin.
Peers · Healthcare
DNAPrint Genomics, Inc.——Panacea Life Sciences Holdings, Inc.——Perimeter Medical Imaging AI, Inc.39DFemasys Inc.41DAdynxx, Inc.——Horizon Space Acquisition II Corp.——Neighbors
Suffolk →Key facts
CEORobert T. Connelly
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeNASDAQ: ELTX
Employees33
IPO date2021-02-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.